A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies

Cancer, 05/11/2012

Efatutazone demonstrates acceptable tolerability with evidence of disease control in patients with advanced malignancies.

Print Article Summary